Milestone Scientific to Present at Investor Summit Group's Q2 In-Person Conference on May 3rd in NYC
The conference is completely complimentary to qualified investors, who can register at Complimentary Investor Registration.
Roseland, New Jersey--(Newsfile Corp. - April 29, 2022) - Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that Arjan Haverhals, President and CEO of Milestone Scientific, will present at The Q2 Investor Summit, hosted by the Investor Summit Group, being held on May 3-4, 2022 at The Westin New York Grand Central.
Event: The Q2 Investor Summit Group
Date: May 3-4, 2022
Location: The Westin New York Grand Central
212 E 42nd St, New York, NY 10017
Presentation: May 3rd at 9:30 AM ET
Webcast: https://us06web.zoom.us/webinar/register/WN_4I4_LaamSPWJf29XWtNlzw
Management will also host 1x1 meetings with qualified investors throughout the conference. The conference is completely complimentary to qualified investors, who can register at Complimentary Investor Registration.
About the Investor Summit Group
The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit Group will take place in-person, featuring 65+ companies and over 300 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. [email protected]
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020
# # #
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/122208